379 related articles for article (PubMed ID: 25892884)
1. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
Su SB; Qin SY; Chen W; Luo W; Jiang HX
World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
4. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
[TBL] [Abstract][Full Text] [Related]
5. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.
Liao WC; Wu MS; Wang HP; Tien YW; Lin JT
Pancreas; 2009 May; 38(4):422-6. PubMed ID: 19214136
[TBL] [Abstract][Full Text] [Related]
6. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
7. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
9. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
10. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
11. Serum Carbohydrate Antigen 19-9 in Differential Diagnosis of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis.
Cao S; Hu Y; Gao X; Liao Q; Zhao Y
PLoS One; 2016; 11(11):e0166406. PubMed ID: 27835676
[TBL] [Abstract][Full Text] [Related]
12. Comparison of platelet-lymphocyte ratio and CA 19-9 in differentiating benign from malignant head masses in patients with chronic pancreatitis.
Kakkat S; Rajan R; Sindhu RS; Natesh B; Raviram S
Indian J Gastroenterol; 2017 Jul; 36(4):263-267. PubMed ID: 28916969
[TBL] [Abstract][Full Text] [Related]
13. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
14. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?
Bedi MM; Gandhi MD; Jacob G; Lekha V; Venugopal A; Ramesh H
Indian J Gastroenterol; 2009; 28(1):24-7. PubMed ID: 19529898
[TBL] [Abstract][Full Text] [Related]
15. Serological characteristics of autoimmune pancreatitis and its differential diagnosis from pancreatic cancer by using a combination of carbohydrate antigen 19-9, globulin, eosinophils and hemoglobin.
Yan T; Ke Y; Chen Y; Xu C; Yu C; Li Y
PLoS One; 2017; 12(4):e0174735. PubMed ID: 28369140
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of diagnostic value of serum Carbohydrate antigen 199 in pancreatic cancer.
Zhang Y; Jiang L; Song L
Minerva Med; 2016 Feb; 107(1):62-9. PubMed ID: 26824636
[TBL] [Abstract][Full Text] [Related]
17. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
[TBL] [Abstract][Full Text] [Related]
18. Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies.
Yang Y; Yan S; Tian H; Bao Y
Medicine (Baltimore); 2018 Mar; 97(9):e9994. PubMed ID: 29489701
[TBL] [Abstract][Full Text] [Related]
19. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
20. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
Deng T; Yuan Y; Zhang C; Zhang C; Yao W; Wang C; Liu R; Ba Y
Cell Physiol Biochem; 2016; 39(5):1716-1722. PubMed ID: 27639768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
